BiotechTube
Diabeloop

Diabeloop

Grenoble, France· Est.
diabeloop.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $115M

Overview

Diabeloop is a Grenoble-based medtech pioneer commercializing a CE-marked and FDA-authorized AID system (DBLG2) for Type 1 diabetes, powered by a self-learning AI algorithm. The company has secured significant funding (€70M Series C in 2022) and established key international partnerships with major diabetes care players like Roche, Terumo, and Novo Nordisk to drive expansion. Its strategy focuses on interoperability, extending its AI platform to connected insulin pens for Type 2 diabetes, and pursuing global market access in the US, Japan, and Korea.

Metabolic

Technology Platform

Self-learning therapeutic AI algorithm for automated insulin delivery and decision-support, designed for interoperability with continuous glucose monitors, insulin pumps, and connected insulin pens.

Funding History

3
Total raised:$115M
Series C$70M
Series B$31M
Series A$14M

Opportunities

The massive and growing global diabetes population, particularly Type 2 patients on injection therapy, represents a largely untapped market for digital solutions.
Diabeloop's interoperable AI platform strategy allows it to partner with major device and pharma companies to rapidly scale without bearing all hardware development costs.
Expansion into the US, Japan, and Korea provides access to large, advanced healthcare markets.

Risk Factors

Facing intense competition from large, established AID system manufacturers with greater resources and market presence.
Heavy reliance on the success and timelines of multiple external partners for hardware and commercialization introduces execution risk.
Navigating complex and varying regulatory and reimbursement landscapes in target international markets remains a significant challenge.

Competitive Landscape

Diabeloop competes in the Automated Insulin Delivery (AID) market against integrated players like Medtronic (MiniMed 780G), Tandem Diabetes Care (t:slim X2 with Control-IQ), and Insulet (Omnipod 5). Its differentiation is its advanced, self-learning AI and an interoperability-focused platform strategy. In the connected insulin pen space, it faces competition from other digital therapy management platforms and direct pen manufacturers adding smart features.

More companies in Digital Health & Biotech SaaS →More companies in France →